索磷布韦/维帕他韦治疗基因1-4型HCV感染肝移植受者12周
这项研究评估索磷布韦/维帕他韦(SOF/VEL)400/100 mg每日一次治疗12周在肝移植后基因1-4型HCV复发感染成人中的安全性和有效性。共79例患者入组,SVR12率为96%,1例因高血糖停药,无严重不良事件、移植肝排斥或死亡。
要点
- 肝移植后基因1-4型HCV复发感染患者接受SOF/VEL 12周,SVR12率达96%。
- 基因1、2、3、4型SVR12率分别为95%、100%、97%、100%。
- 1例因高血糖停用SOF/VEL,无研究者认定的SOF/VEL相关严重不良事件。
核心结论
- SOF/VEL治疗12周在伴或不伴肝硬化的基因1-4型HCV感染肝移植受者中高度有效且耐受性良好。
研究设计与样本
- 研究纳入肝移植后基因1-4型HCV复发感染的成人患者,接受SOF/VEL 400/100 mg每日一次治疗12周。
- 患者可为经治或初治,无肝硬化或伴代偿期肝硬化。
- 共79例患者入组并接受治疗:基因1型37例(47%)、基因2型3例(4%)、基因3型35例(44%)、基因4型4例(5%)。
- 主要终点为SVR12和因不良事件停药。
主要发现
- 总体SVR12率为96%。
- 按基因型,SVR12率分别为基因1型95%、基因2型100%、基因3型97%、基因4型100%。
- 2例患者出现病毒学复发:1例基因1a型感染、无肝硬化且初治;1例基因3型感染、无肝硬化且经治。
- 1例患者因高血糖停用SOF/VEL。
- 研究者未认定任何严重或重度不良事件与SOF/VEL相关,研究期间无肝移植排斥或死亡发生。
关键数值与推荐
- SOF/VEL剂量为400/100 mg每日一次,疗程12周。
- 81%为男性,82%为白人,18%伴代偿期肝硬化,59%为经治患者。
- 最常用免疫抑制剂为他克莫司(71%)、麦考酚酸(24%)、环孢素(14%)和硫唑嘌呤(11%)。
- 肝移植至入组的中位(范围)时间为7.5(0.3,23.9)年。
- 临床试验注册号:NCT02781571。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Sofosbuvir, an NS5B inhibitor, combined with velpatasvir, an NS5A inhibitor (SOF/VEL), produces high sustained virologic response rates 12 weeks after treatment (SVR12) in patients with genotype 1-6 HCV infection, and has no anticipated clinically relevant drug-drug interactions with immunosuppressants. This study evaluated the safety and efficacy of SOF/VEL in adults with recurrent chronic genotype 1-4 HCV infection after liver transplant. METHODS: Patients received SOF/VEL 400/100 mg daily for 12 weeks. Patients could be treatment experienced or treatment naïve with no cirrhosis or with compensated cirrhosis. The primary endpoints were SVR12 and discontinuations due to adverse events. RESULTS: A total of 79 patients were enrolled and treated in this study (37 [47%] had genotype 1, 3 [4%] genotype 2, 35 [44%] genotype 3, and 4 [5%] genotype 4 HCV). Of these, 81% were male, 82% were white, 18% had compensated cirrhosis, and 59% were treatment experienced. The most commonly used immunosuppressants were tacrolimus (71%), mycophenolic acid (24%), cyclosporine (14%), and azathioprine (11%). Median (range) time from liver transplantation was 7.5 (0.3, 23.9) years. The SVR12 rate was 96%. By genotype, SVR12 rates were 95% (genotype 1), 100% (genotype 2), 97% (genotype 3), and 100% (genotype 4). Two patients experienced virologic relapse: one with genotype 1a infection was non-cirrhotic and treatment naïve, and one with genotype 3 infection was non-cirrhotic and treatment experienced. One patient discontinued SOF/VEL due to hyperglycemia. No serious or severe adverse events were deemed SOF/VEL-related by the investigator, and no liver transplant rejection episodes or deaths occurred during the study period. CONCLUSIONS: Treatment with SOF/VEL for 12 weeks was highly effective and well tolerated in genotype 1-4 HCV-infected liver transplant recipients with and without cirrhosis. LAY SUMMARY: Sofosbuvir/velpatasvir is a combination of two drugs in one tablet that is approved for the treatment of patients with chronic hepatitis C virus (HCV) infection. When patients with chronic HCV infection receive a liver transplant, the HCV infection usually recurs, and damages the transplanted liver. This study tested the effects of 12 weeks of sofosbuvir/velpatasvir treatment in patients who had HCV recurrence after a liver transplant. Three months following the end of treatment, 96% of patients were cured of HCV infection. Clinical trial number: NCT02781571.
引用
- Agarwal K, Castells L, Müllhaupt B, et al. Sofosbuvir/velpatasvir for 12 weeks in genotype 1-4 HCV-infected liver transplant recipients. J Hepatol. 2018. PMID: 29886154. doi:10.1016/j.jhep.2018.05.039
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。